How Does Glaukos Company Work?

Glaukos focuses its efforts on three key areas: glaucoma, corneal disorders, and retinal diseases. Their product portfolio includes established solutions and pioneering new therapies designed to improve patient outcomes.

In the glaucoma segment, Glaukos offers leading products like the iStent inject W, iStent infinite, PRESERFLO MicroShunt, and the iDose TR. The iDose TR represents a significant advancement as a sustained-release pharmaceutical for intracameral delivery of medication.

For corneal disorders, Glaukos provides the sole FDA-approved corneal cross-linking therapy for keratoconus, utilizing a proprietary bio-activated pharmaceutical. The company is also advancing its pipeline with sustained-release drug delivery platforms for retinal diseases.

Glaukos demonstrates a strong commitment to innovation, investing over $700 million in research and development since 2018. This investment has expanded their disclosed pipeline programs from 4 in 2015 to 14 by 2025.

Glaukos's history is marked by foundational achievements, including the creation of the MIGS market in 2012. The company's strategic pipeline advancements in 2025 include the FDA's acceptance for review of the NDA submission for Epioxa (Epi-on), with a PDUFA date set for October 20, 2025. Additionally, a 510(k) pivotal study for PRESERFLO MicroShunt began in April 2025.

The company has adeptly managed market challenges, such as the impact of Local Coverage Determinations on its U.S. Glaucoma stent business and reimbursement complexities for iDose TR. The expiration of the Hydrus Microstent royalty on April 26, 2025, and entry into the Medicaid Drug Rebate Program in 2024, which affected Photrexa revenues, are other factors Glaukos has navigated.

Glaukos maintains a strong competitive advantage through its technological leadership, evident in its pioneering role in MIGS and the development of novel 'dropless platform technologies.' The company's commitment to innovation is underscored by over $700 million invested in R&D since 2018.

As of the first quarter of 2025, Glaukos reported approximately $303.4 million in cash and cash equivalents with no outstanding debt. This robust financial position supports its ongoing adaptation and growth strategies within the glaucoma treatment market.

Glaukos holds a leading position in the ophthalmic medical technology industry, especially for its foundational role in Micro-Invasive Glaucoma Surgery (MIGS). The company aims to be a global leader in novel ophthalmic therapies, supported by direct operations in 17 countries and over 300 commercial personnel as of January 2025.

The company faces risks including regulatory hurdles, lengthy approval processes, and increasing competition in international markets. Changes in Local Coverage Determinations (LCDs) and professional fee reimbursement for certain procedures also present ongoing challenges to its U.S. glaucoma stent business.

Glaukos is focused on advancing its pipeline of dropless platform technologies to improve patient outcomes and reshape glaucoma management, exemplified by iDose TR. The company reaffirmed its 2025 net sales guidance of $475 million to $485 million, indicating confidence in continued growth through innovation and market expansion.

Despite a negative free cash flow of -$17.66 million due to significant R&D and market expansion investments, analyst sentiment is largely positive, with a consensus of 12 buy ratings and a potential upside of 25.34%. The company plans to enhance profitability through ongoing innovation and disciplined execution.